Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study
Rishi Lulla(Northwestern University), Maryam Fouladi(Nationwide Children's Hospital), Shengjie Wu(Sir Run Run Shaw Hospital), Michael Pacini(Northwestern University), Linda R. Bressler(University of Chicago), Roger J. Packer(Children's Hospital of Philadelphia), Girish Dhall(Northwestern University), Ira J. Dunkel(Memorial Sloan Kettering Cancer Center), Stewart Goldman(St Nicholas Hospital), Ian F. Pollack(Children's Hospital of Pittsburgh), James M. Boyett(University of Illinois Chicago), Craig W. Beattie(Abbott (Canada)), Paul G. Fisher(Northwestern University), Arzu Onar(Northwestern University), Tohru Yamada(Illinois College)
Cited by 140
Related Papers
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma
|Nature Medicine|2015|711
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
|Acta Neuropathologica|2016|650